The incidence of coronary artery disease is markedly increased in patients with insulin resistance such as those with Type II (non-insulin-dependent) diabetes mellitus or obesity. Reduced endogenous fibrinolytic system capacity secondary to increased expression of plasminogen activator inhibitor type-1 (PAI-1) has been implicated as one of multiple aetiologic factors [1] . Insulin can stimulate PAI-1 synthesis in adipocytes in vitro and in vivo [2, 3] . In insulin resistant subjects, proinsulin can constitute more than 50 % of the total of insulin-like molecules in blood [4] . This study was designed to determine whether proinsulin can contribute to increased expression of PAI-1 in intra-abdominal adipose tissue in vivo thereby potentially augmenting PAI-1 concentrations in blood resulting, in part, from PAI-1 originating in visceral fat. Rabbits were studied because of well established Diabetologia (2001) Abstract Aims/hypothesis. Impaired fibrinolytic system capacity secondary to increased plasminogen activator inhibitor type-1 expression has been suggested as a pathogenetic link between insulin resistance and increased cardiovascular risk in patients with Type II (non-insulin-dependent) diabetes mellitus, obesity, or both. In patients with syndromes of insulin resistance including those with Type II diabetes, precursors of insulin such as proinsulin can constitute more than 50 % of insulin-like molecules in blood. The aim of this study was to determine whether proinsulin can increase plasminogen activator inhibitor type-1 expression in intra-abdominal adipose tissue in vivo, potentially contributing to the increased PAI-1 seen with insulin resistance. Methods. Lightly sedated normal rabbits were given intravenous proinsulin, insulin, or vehicle alone under euglycaemic clamp conditions with serial sampling of blood and assessment of PAI-1 expression in visceral fat.
pling of blood and assessment of PAI-1 expression in visceral fat.
Results. Both proinsulin and insulin increased expression of plasminogen activator inhibitor type-1 in intra-abdominal adipose tissue, 5.3-fold (p = 0.006 vs control) and 2.5-fold (p = 0.031 vs control) respectively. PAI-1 inhibitor activity in blood peaked 3 h after administration of each, 5.1-fold, p = 0.020, and 3.4-fold, p = 0.004, respectively but did not change under control conditions. Conclusion/interpretation. Hyperproinsulinaemia can contribute to increased expression of plasminogen activator inhibitor type-1 in intra-abdominal adipose tissue implicated in increasing PAI-1 activity in blood, impaired fibrinolysis, and accelerated atherogenesis typical of Type II diabetes. [Diabetologia (2001) 
44: 1121±1124]
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Proinsulin given intravenously is not converted to insulin appreciably within the first 24 h after its administration [7] . Its effect on PAI-1 expression was compared with that of insulin. Visceral, rather than subcutaneous, adipose tissue was characterized because others have shown that intra-abdominal adipose tissue is a determinant of blood concentrations of PAI-1 and that PAI-1 production in human intraabdominal adipose tissue-explants is substantially greater than that in subcutaneous fat explants from the same subjects [8] .
Materials and methods
Materials. Human insulin (26 U/mg) and glucose were purchased from Sigma (St. Louis, Mo., USA). Human proinsulin was provided by Eli Lilly (Indianapolis, Ind., USA). Contamination with endotoxin was excluded in all reagents and vehicles by testing with Limulus amebocyte lysate (Pyrotell assay, Associated of Cape Cod; sensitivity for detection of endotoxin, 0.0125 ng/ml).
Procedures in animals.
Care and handling of rabbits conformed with the guidelines of the University of Freiburg Committee on Human Care of Laboratory Animals and with the Declaration of Helsinki Standards. New Zealand White rabbits (3.7 0.5 kg body weight, mean SD) were tranquillized and maintained as described previously [6] . Anesthesia was avoided to preclude physiologic stress, consequent release of corticosteroids, catecholamines, and other hormonal derangements, resulting in increased free fatty acid concentrations in blood and hyperlipidaemia which can increase expression of PAI-1. Rabbits were randomly treated with intravenous 1-hr infusions of vehicle alone (control), insulin (37 mg/kg body weight), or proinsulin (61 mg/kg body weight, equimolar to insulin) and maintained euglycaemic by glucose clamping. To maintain euglycaemia, blood glucose was monitored every 10 min and exogenous glucose (20 %) was infused at an adjusted rate through a separate venous catheter until the concentration of blood glucose was stable in the absence of continuing infusion (usually at about 3 h). The concentration of insulin used (1 U/kg body weight) was selected to yield concentrations in blood in the upper range of that seen in patients with Type II diabetes mellitus. The concentrations seen at 1 h (the time when the infusion of insulin, proinsulin, or vehicle was terminated) were 688 142 mU/ml for insulin and 44.2 2.8 nmol/l for proinsulin.
Activity of PAI-1 in plasma. Blood samples were acquired before infusions were initiated and 3 h later by which time increases in PAI-1 activity in blood had peaked. PAI-1 activity was assayed spectrophotometrically after incubation of samples with excess exogenous t-PA [6] . One arbitrary unit (AU) was defined as the amount of PAI-1 activity that inhibited 1 IU of t-PA.
Quantification of PAI-1 mRNA in adipose tissue. Intra-abdominal adipose para-aortic tissue samples were acquired 3 h after the onset of infusions. RNA was extracted. Concentrations of PAI-1 mRNA and of GAPDH mRNA were quantified as described previously [6, 9] . Statistical analysis. Results are means SEM. The significance of differences between group means was assessed by ANOVA and two-tailed Student's t test for paired or unpaired observations as appropriate. Statistical significance was defined as a p value of less than 0.05.
Results
PAI-1 activity in blood. Activity of PAI-1 in blood before (at 0 h) and 3 h after initiation of infusions are shown (Fig. 1) . In control animals plasma PAI-1 activity did not change. By contrast, infusion of insulin increased PAI-1 activity 3.4-fold (p = 0.004). Infusions of proinsulin increased it 5.1-fold (p = 0.020). PAI-1 activity in blood after infusions of both insulin and proinsulin were significantly higher than those in control animals at comparable intervals after the onset of infusions (control compared with insulin, p = 0.003; control compared with proinsulin, p = 0.009; insulin compared with proinsulin, p = NS).
Expression of PAI-1 in adipose tissue. Rabbits express only one PAI-1 mRNA species (3.2 kb) in contrast to humans in which two forms are typical [5] . Three hours after the onset of infusion, animals given insulin had a 2.5-fold higher expression of PAI-1 in visceral adipose tissue, and those given proinsulin had a 5.3-fold higher expression of PAI-1 in intra-abdominal adipose tissue compared with values in control animals. All values were normalized for expression of GAP-DH, mRNA. Thus, comparisons of results under the conditions studied were significant with the following p values: control compared with insulin, p = 0.031; control compared with proinsulin, p = 0.006; and insulin compared with proinsulin, p = 0.049 (Fig. 2) . 
Discussion
We found that the insulin precursor, proinsulin, increases expression of PAI-1 in intra-abdominal adipose tissue under euglycaemic conditions in vivo as does insulin itself. These results are consistent with previous results obtained with murine preadipocytes differentiated to adipocytes in vitro. Such cells exhibited increased expression of PAI-1 protein in the presence of insulin and TNF-a, each alone and together synergistically [2] . Induction of PAI-1 protein as well as augmentation of PAI-1 mRNA by insulin have been observed in human adipose tissue explants and in differentiated adipocytes from murine 3T3 cells [3] . However, PAI-1 expression did not increase in human adipocytes and cultured human stroma cells isolated with collagen in response to insulin. Thus, interactions between diverse cell types within adipose tissue could influence induction of PAI-1 expression by insulin and proinsulin. The specific cellular or subcellular locus of increased PAI-1 expression which we observed within the adipose explants is yet to be found.
Increased expression of PAI-1 induced by proinsulin in intra-abdominal adipose tissue in vivo has not been observed. However, others have shown that intraperitoneal injection of insulin in lean mice induces a several-fold increase in PAI-1 expression in epididymidal fat tissue [10] . The animals studied were not maintained under euglycaemic conditions. Thus, physiologic stress and increased glucocorticoid release secondary to hypoglycaemia could have contributed to the increased PAI-1 expression observed [3] . Furthermore, although epididymidal fat cells resemble intra-abdominal adipocytes morphologically, they could differ functionally. Accordingly, we sought to determine whether intra-abdominal adipose tissue PAI-1 expression increased in vivo in response to insulin, proinsulin, to neither, or both.
Normal rabbits were selected for this purpose because of well established parallels between the regulation of endogenous fibrinolysis in rabbits and in humans [5, 6] . We elected to use normal, in contrast to experimental, animal preparations manifesting features of Type II diabetes, to determine potential associations between induced hyper(pro)insulinaemia and increased expression of PAI-1 in visceral adipose tissue independent of other factors such as hyperglycaemia, dyslipidaemia, or insulin resistance prevalent in Type II diabetes which might influence PAI-1 expression alone or in combination with the infused agents. Obese animals were selected for the same reasons. In addition, in lean animals sufficient amounts of intra-abdominal adipose tissue would be difficult to acquire.
Blood concentrations of PAI-1 are influenced by expression of PAI-1 in adipose tissue, predominantly in intra-abdominal fat. In obese human subjects, weight loss induced surgically or with dietary regimens reduces blood concentrations of PAI-1 [11±14]. The change is closely related to changes in the mass of intra-abdominal fat. In fact, it reflects such changes more closely than it parallels changes in concentrations of metabolites such as triglycerides in blood [15] . Moreover, increased expression of PAI-1 in intra-abdominal as opposed to subcutaneous fat seems to be a determinant of changes in blood concentrations of PAI-1 in humans [16±18] . In concert, available data indicate that abdominal adipose tissue in addition to liver and endothelium is a major contributor to PAI-1 activity in blood.
In human subjects with hyperinsulinaemic states more than 50 % of immunoreactive, insulin-like mol- SEM of results of duplicate measurements from four rabbits in each of the three groups ecules in circulating blood comprise precursors of insulin such as proinsulin. In contrast, under physiological conditions they account for only 10 to 20 % of insulin-like molecules [4] . Although the interaction of proinsulin compared with insulin with the insulin receptor is modest (1 %), proinsulin is cleared more slowly from the circulation than is insulin, thereby intensifying and prolonging pathophysiological consequences of hyperproinsulinemia [19] . Our results show that proinsulin is at least as effective on a molar basis as insulin in inducing PAI-1 expression in intraabdominal adipose tissue and increasing PAI-1 activity in blood.
In conclusion, proinsulin as well as insulin in vivo under euglycaemic conditions induce expression of PAI-1 in intra-abdominal adipose tissue and increase PAI-1 activity in blood under euglycaemic conditions. Accordingly, attenuation of impaired fibrinolytic system capacity and its potentially adverse effects in accelerating atherosclerosis could result from normalization of concentrations of proinsulin and insulin in plasma, reduction of intra-abdominal fat mass, or both.
